Innovative Skin Models Genoskin's proprietary technology that preserves viable human skin for up to seven days offers a unique and authentic platform for testing pharmaceuticals, vaccines, and cosmetics, presenting a compelling opportunity for companies seeking human-relevant testing solutions.

Expanding Product Portfolio Recent launches like VaxSkin and ImmunoSafe demonstrate Genoskin's focus on advancing vaccine and immunogenic drug testing, opening avenues for collaborations with vaccine developers and immunotherapy firms aiming for more accurate human response data.

Strong Funding Growth With an $8.7 million Series A funding round and current revenues between $1M and $10M, Genoskin is positioned for accelerated growth and expanding business opportunities in the biotech research and CRO sectors.

Emerging Market Focus Genoskin's emphasis on human skin biology and immune response assessment aligns with market trends favoring biomimetic and human-relevant testing platforms, making it an attractive partner for companies seeking alternative models to animal testing.

Technology & Data Expertise Leveraging advanced assays such as imaging, next-generation sequencing, and its proprietary in vitro platforms enables Genoskin to deliver high-quality, reliable data, which can be a critical differentiator for clients requiring precision and regulatory compliance.